Stay up-to-date with the latest announcements from TranS1 about our minimally invasive spine products, upcoming events, and more.
February 13th, 2018
TranS1® Announces Three New Patents
Spinal device company expands portfolio of innovative devices with a goal of improving patient outcomes and reducing hospital stays
Denver, Feb. 13, 2018 (GLOBE NEWSWIRE) — TranS1®, a spinal device company focused on breakthrough solutions that minimize tissue trauma, today announced it has added three new patents to its portfolio. The patents relate to two new developments associated with presacral interbody fusion, including two new expandable cages designed to create lordosis at L5-S1, along with a new technique to perform sacroiliac (SI) fusion.
“TranS1’s patent portfolio remains one of the strongest in the industry,” said Jeffrey Schell, chief executive officer of TranS1, who is also a patent attorney. “Our strategy remains to advance the most innovative technologies to lessen tissue trauma during spine surgery and to vigorously guard those technological innovations through domestic and international patent protection.”
TranS1 offers a full complement of minimally invasive surgery (MIS) solutions for spinal pathologies, including the award-winning Pylon™ posterolateral decortication and bone graft placement system, the KeyLIF™ MIS Oblique Lateral Interbody Fusion system and the AxiaLIF® presacral interbody fusion system.The AxiaLIF procedure allows for minimally invasive spinal fusion at L5-S1 for patients with certain spinal pathologies. Presacral interbody fusion at L5-S1 was awarded a Category 1 CPT® Code (22586) in 2013 by the American Medical Association’s CPT Editorial Committee. According to the CPT Editorial Panel, procedures recognized as Category 1 are widely performed throughout the United States, consistent with accepted medical practice and supported by relevant published research demonstrating the clinical efficacy of the procedure.
In addition to its full suite of MIS procedures and devices, TranS1 has also created and continues to develop a patent portfolio focused on spinal health technologies. The company remains committed to becoming the most innovative in the industry by developing new technologies, applying lessons learned from its development of related approaches, and by attracting the most experienced engineers and surgeons to its team. In all, TranS1 has more than 100 issued patents and has filed more than 50 new patent applications in the last three years.
Headquartered in Denver, TranS1 develops medical breakthroughs to solve spinal pathologies that minimize trauma to the tissues surrounding the spine. The company’s flagship product, AxiaLIF+, is a minimally invasive option for surgeons to accomplish spinal fusion at the L5-S1 joint. The company was named Denver’s Most Innovative Workplace by the 80/95 Awards, presented by the Denver Post. In 2017, the company won the “New Spine Technology” award from Orthopedics This Week for its Pylon™ MIS Posterolateral Decortication and Bone Graft Placement System. For more information, visit www.TranS1.com.
# # #
September 28th, 2017
TranS1® and CU Innovations Partner to Commercialize Ideas Originating at Anschutz Medical Campus
Unique new partnership seeks to assess the value, validity and commercial potential of innovations ideated at the University of Colorado Anschutz Medical Campus
Denver — Sept. 28, 2017 — TranS1®, a med-tech company creating advanced surgical options for better pathways to patient care, announced today a partnership with CU Innovations and Orthopedic Surgery at the University of Colorado Anschutz Medical Campus. CU Innovations works directly with CU researchers to bring their innovative ideas and concepts to the marketplace, to help improve the lives of patients and for public benefit. By working with industry partners like TranS1 to perform efficient concept evaluation and product development, CU Innovations brings critical expertise to the valuable work of CU’s researchers.
“It’s a remarkable demonstration of forward thinking and adaptability by CU Innovations to leverage the strengths and resources of local industry partners, and we hope it will spur academic medical centers around the country to adopt a similar innovative approach,” said Jeff Schell, CEO of TranS1.
The TranS1-CU Innovations partnership encourages researchers at the University to progress their innovative ideas within the field of spinal health in cooperation with TranS1, which provides a complete portfolio of research and development (R&D) capabilities to support surgeons and other members of the Anschutz family throughout the product development life cycle.
“One of the most important aspects of the partnership we are forging with TranS1 is the company’s ability to apply its deep expertise in product development and its commercial infrastructure to our concepts and our innovations here on campus. These capabilities can’t be created overnight and we are fortunate to have Trans1 right here in Denver, to bring new surgical technologies to the operating room, and improve outcomes for patients” said Brian Bellesheim, Business Development at CU Innovations.
“The relationship with TranS1 has given us the ability to find a marketable pathway to progress with an idea in a way that was not possible before,” said Dr. Vikas Patel, M.D., M.A., Chief of Orthopedic Spine Surgery at CU Anschutz.
“As we began talking to Dr. Patel, it became very clear that he had several ideas for how he thought spine surgery could be made better, and that fits directly with the TranS1 mission,” said Schell.
Schell began his career as a patent attorney and the founder of the Denver-based Rocky Mountain Patent law firm. Schell’s knowledge and experience as a patent attorney led to his creation of TranS1’s surgeon-driven concept-to-market program.
“Having in-house executives with substantial IP knowledge at TranS1 means that we can assess patent-strategy on ideas from CU while we explore whether the concepts are technically feasible and will lead to better patient outcomes. It’s a more efficient way to engage in R&D in the medical device field, leading to quicker decisions, and to creating better pathways for surgeons and patients,” Schell said.
TranS1 focuses on surgeon-led innovation. The company believes that no one is better positioned to solve complex problems in the operating room than surgeons themselves, and it’s TranS1’s job to translate these innovative solutions into breakthrough medical devices.
For more information, a video is available here.
TranS1 develops products that provide pathways to better treatment through advanced options for surgeons. The company’s flagship product, AxiaLIF+®, is a minimally invasive option for surgeons to accomplish spinal fusion at the L5-S1 joint. For more information, please visit www.trans1.com.
About University of Colorado | Anschutz Medical Campus
The University of Colorado | Anschutz Medical Campus is a premier academic medical center and home to nearly five thousand faculty, three leading healthcare systems and conducts nearly half a billion dollars a year in biomedical research, for public benefit. CU Innovations directs technology commercialization at the University of Colorado | Anschutz Medical Campus and on behalf of its hospital affiliates; UCHealth and Children’s Hospital Colorado. Orthopedic Surgery is housed in the CU School of Medicine, Department of Orthopedics.
February 21st, 2017
TranS1 launches Capital Bone Graft Harvester
New technology provides surgeons with MIS solution for autologous bone capture
DENVER — Feb. 21, 2017 — TranS1®, a medical device company focused on breakthrough spine solutions that minimize tissue trauma, today announced the release of the Capital Bone Graft Harvester, a new technology that allows for fast, reliable, and reproducible harvesting of autograft material from the iliac crest.
“Cancellous bone from the iliac crest is the gold standard for fusion,” said Jeff Schell, President and CEO of TranS1. “The innovative design of the Capital Bone Graft Harvester is intended to solve the deficiencies with traditional iliac crest harvesting approaches and provide surgeons a reproducible MIS autograft solution for use in spine procedures.”
Unlike the traditional open approach, the Capital Bone Graft Harvester allows access to the iliac crest with a one centimeter tissue access dilator. All grafting is performed through that opening. The unique construction of the instrumentation creates access for the capture of bone by utilizing ridges within the tube internal diameter. Shaft fenestration facilitates bone drilling and capture while providing ease of autograft ejection. The device also extracts the graft dowel while shielding surrounding tissue. The iliac crest is targeted using a true anterior posterior fluoroscopic image. Based on surgeon preference, the iliac crest may be accessed from a lateral or prone patient position.
The result, unlike other bone graft substitutes, is a natural sample of the patients’ own bone that can be used in a fusion surgery and contains osteoinductive, osteoconductive, and osteogenic properties. The Capital Bone Graft Harvester is one of several technologies TranS1 has released over the past six months. The company offers a full suite of MIS solutions for spine to compliment its flagship, the AxiaLIF+® System for pre-sacral interbody fusion. The Capital Bone Graft Harvester is patent pending and is currently available on the market.
TranS1® develops medical breakthroughs to solve spinal pathologies that minimize trauma to the tissues surrounding the spine. The company’s flagship product, AxiaLIF+®, is a minimally invasive option for surgeons to accomplish spinal fusion at the L5-S1 joint. The Colorado-based company was named Denver’s Most Innovative Workplace by the 80/95 Awards, presented by the Denver Post. For more information, please visit www.TranS1.com.
1 Le Pape, Du Pouget, Cloche, Campana, Obeid, Boissiere, Vital. (2016) “Anatomic feasibility of a new endopelvic approach for iliac crest bone harvesting.” Surgical and Radiologic Anatomy. Dec;38(10):1191-1194.
2 Prasanna Kumar, Belliappa Vinitha, and Ghousia Fathima. (2013) “Bone Grafts in Dentistry.” Jun; 5(Suppl 1): S125–S127.doi: 10.4103/0975-7406.113312
November 29th, 2016
TranS1 recognized as a leading innovator in Colorado
Denver-based medical device company received accolades from three top business organizations for its 2016 accomplishments
DENVER – November 29th, 2016 – TranS1® today announced that it earned recognition for its efforts in innovation, leadership, and the advancement of new technologies in Colorado from three leading business organizations.
- Winner, Most Innovative Workplace in Denver – TranS1® was recognized at the 80/95 Awards, sponsored by the Denver Post, as the most innovative workplace in Denver. The 80/95 Awards were presented during Millennial Weekend Denver and showcase companies that have millennial leaders who make an impact on culture, enterprise, and society.
- Finalist, Apex Awards – TranS1® was named a finalist for the Colorado Technology Association’s Apex Awards. The Apex Awards recognize Colorado technology excellence, highlighting remarkable leaders and innovators.
- Honoree, Top 250 Private Companies in Colorado – TranS1® was named one of the Top 250 Private Companies in Colorado by ColoradoBiz Magazine. The awards recognize the top 250 private companies in the state by revenue.
“TranS1’s® mission is to develop breakthrough medical innovations, therefore, it is an honor to be recognized by 80/95, Colorado Technology Association, and ColoradoBiz Magazine as a leading innovator in Colorado,” said Jeff Schell, president and CEO of TranS1®. “The strong talent base and business community in Denver are crucial factors in our success.”
TranS1® established operations in Denver in February 2015. The company offers technologies that solve spinal pathologies, including the AxiaLIF+ system, which has been on the market for a decade. TranS1®released a suite of new products in October 2016. Among those products are an MIS Pedicle Screw System, a TLIF/PLIF IBF System, and a Cervical Interbody System. Also in October, the company announced plans to launch the Capital Bone Graft Harvester and Pylon Graft Delivery System in 2017.
“I am proud of our team’s accomplishments in 2016, and with more than 10 new technologies in our pipeline, including multiple proprietary innovations poised to launch, 2017 will prove to be an even bigger year,” Schell explained.
TranS1® develops medical breakthroughs to solve spinal pathologies that minimize trauma to the tissues surrounding the spine. The company’s flagship product, AxiaLIF+®, is a minimally invasive option for surgeons to accomplish spinal fusion at the L5-S1 joint. For more information, please visit www.trans1.com.
April 6th, 2016
TranS1 Names Brandon Arthurs, Vice President of Research & Development
“Brandon Arthurs, a certified professional engineer, will lead collaborations with surgeons and entrepreneurs to bring medical innovations to market. Arthurs brings nearly two decades of successful technical leadership and product development, as well as an extensive track record of securing medical patents.”
February 02, 2016
TranS1 Names Chris Groppa Chief Marketing Officer and Director of Reimbursement
“In this role, Groppa will oversee the development and implementation of all marketing activities and will continue to oversee TranS1’s insurance reimbursement strategy. He brings more than a decade of digital marketing, communications and product development expertise to the TranS1 team.”
November 10, 2015
Economic Analysis Demonstrates Substantial Spine Surgery Cost Savings with TranS1's AxiaLIF+
“The AxiaLIF procedure from TranS1®, a medical device company focused on designing, developing and marketing products to treat degenerative conditions of the spine, provides an estimated savings of $3,500 when compared to the Transformational Lumbar Interbody Fusion (TLIF) surgery option according to a recent study.”
September 21, 2015
TranS1 Announces John Miller as New Vice President of Sales
“Healthcare industry veteran John Miller will lead sales efforts for innovative medical device company’s AxiaLIF® product as well as future offerings”